View all cases
UPC APP 19773/2025
- Case details
- Status—ActionPreliminary objectionCategoryPreliminary objection
- Parties
- Claimants
- Genevant Sciences GmbHNPE
- Arbutus Biopharma CorporationOperating co.
Respondents- Moderna Italy S.R.L.Operating co.
- Moderna France SASUOperating co.
- Moderna Germany GmbHOperating co.
- Moderna Poland Sp. z o.o.Operating co.
- Moderna Netherlands B.V.Operating co.
- Moderna Denmark ApSOperating co.
- Moderna Biotech Spain SLOperating co.
- Moderna Belgium S.R.L.Operating co.
- Moderna Portugal Unipessoal LDAOperating co.
- Division
- The Hague LD
- Judges
- —
- Language
- —
- First decided
- May 23, 2025
How this compares
How long the court takes to reach a first decision.
| Median days to first decision | |
|---|---|
| All UPC | 124 |
| The Hague LD | Locked |
At the UPC: Genevant Sciences GmbH (9 cases)·Moderna Group (20 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
Decisions
- 2025-05-23Preliminary objectionPublic
Summary: Procedural order of The Hague Local Division in infringement proceedings by Genevant Sciences GmbH and Arbutus Biopharma Corporation against multiple Moderna entities concerning lipid nanoparticle delivery technology. The order addresses preliminary objections and jurisdictional matters concerning certain Moderna entities (Moderna Spain, Moderna Poland, Moderna Norway), examining whether their activities constitute or enable infringement within the UPC territory.
Show the legal issues (4)
- Preliminary objection
- Jurisdiction over Moderna entities
- Infringement by enabling/facilitating activities Art. 63 UPCA
- Marketing authorisation as infringing act
Documents
- 5703DF572E9C1DAE62392D39A6CC3315_en.pdf2025-05-23EN